Breaking News

PTC Furthers Workforce Reduction

Impacts ~25% of the company and includes employees working on early-stage research programs and NJ gene therapy manufacturing facility.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

PTC Therapeutics, Inc. is implementing a further strategic prioritization and associated workforce reduction. The portfolio prioritization continues the process initiated in May 2023 to focus resources on its differentiated, high potential R&D programs and on support of the global commercial infrastructure. The company also plans to submit the re-examination request for the CHMP opinion on Translarna.   The workforce reduction impacted approximately 25% of the organization, and primarily i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters